Splicing across adipocyte differentiation is highly dynamic and impacted by the metabolic phenotype
Farris KM., Andersen E., Donkin I., Versteyhe S., Kristiansen VB., Simpson SJ.
Laboratory Study, published in iScience (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- iScience (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41488358
- PMCID
- PMC12756580
- DOI
- 10.1016/j.isci.2025.114119
Abstract (original English)
A better understanding of gene regulation in metabolically unhealthy adipose tissue can provide insights into the mechanisms underlying adipose tissue dysfunction. We used RNA-seq data from a differentiation time course of lean individuals, individuals with obesity, and individuals with obesity and T2D to characterize alternative splicing in adipocyte function. Splicing was highly dynamic across adipocyte differentiation, and the dynamics of splicing were impacted by metabolic phenotype. There was little overlap between genes that were differentially spliced and those that were differentially expressed, positioning alternative splicing as an independent regulatory mechanism whose impact would be missed when looking at gene expression changes alone. We integrated our splicing results with GWAS for BMI and T2D, and found that T2D-associated variants were enriched in regions that were differentially spliced in early differentiation. These findings provide insight into the role of splicing in adipocyte differentiation and serve as a resource to guide variant-to-function studies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.